Building upon second-generation CAR T constructs, it has been hypothesized that additional IL-12 – a cytokine normally generated from antigen-presenting cells that promotes CD8+ T cell activation through increased IFNƴ secretion – may further improve CAR T cell proliferation and anti-tumor activity, as well as assist in overcoming inhibitory factors associated with the tumor microenvironment [62]. Here, CD8A is linked to neoplasm.